Top Markets
#1 Zora Zora +31.68%
#2 AI XOVIA AI XOVIA +30.82%
#3 Full Moon Full Moon +18.72%
#4 0G 0G +17.40%
#5 Notcoin Notcoin +16.40%
#6 Wrapped NXM Wrapped NXM +11.91%
#7 rsERG rsERG +11.83%
#8 Seeker Seeker +10.75%
#9 Axelar Axelar +10.62%
#10 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +10.43%
Coin of the day
Zora Zora
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Silence Therapeutics plc Silence Therapeutics plc

Silence Therapeutics plc

SLN
Classifica tra le azioni #12014
Silence Therapeutics plc is a London, UK-based biotechnology company... Silence Therapeutics plc is a London, UK-based biotechnology company specializing in the research and development of groundbreaking ribonucleic acid (RNA) therapeutics. Its therapeutic focus areas include hematological, cardiovascular, and various rare and metabolic conditions. Central to their innovative approach is the mRNAi GalNAc Oligonucleotide Discovery platform, which is designed for precise targeting of specific disease-causing genes within the liver. The company's methodology harnesses the body's natural RNA interference (RNAi) mechanism by designing short interfering RNA (siRNA) molecules that degrade messenger RNA (mRNA), thereby preventing the production of targeted disease-associated proteins. Their pipeline features several promising candidates, including SLN360, currently in Phase I clinical trials for cardiovascular disease associated with elevated lipoprotein. Another key candidate, SLN124, is undergoing Phase I clinical trials for non-transfusion-dependent thalassemia and myelodysplastic syndrome, with further development planned for polycythemia vera. Silence Therapeutics also engages in strategic collaborations to expand its reach. It has agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for cardiovascular, renal, metabolic, and respiratory diseases. Furthermore, a partnership with Mallinckrodt Pharma IP Trading DAC aims to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company is also collaborating with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three unspecified targets, utilizing Silence's mRNAi GOLD platform. Originally incorporated as SR Pharma plc, the company rebranded to Silence Therapeutics plc in May 2007.
Prezzo delle azioni
$13.34
Ultima sincronizzazione: 2026-08-28
Capitalizzazione di mercato
$629.93M
Variazione (1 giorno)
-0.84%
Variazione (1 anno)
177.26%
Paese
GB
Scambia Silence Therapeutics plc (SLN)

Categoria

Healthcare
Numero di azioni in circolazione per Silence Therapeutics plc (SLN)
Numero di azioni in circolazione al August 2026: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Silence Therapeutics plc, il numero attuale di azioni in circolazione è 0. Alla fine del August 2026, la società aveva 0 azioni in circolazione. Il numero di azioni in circolazione è solitamente influenzato da split azionari e riacquisti.
Storico delle azioni in circolazione di Silence Therapeutics plc (SLN) dal 2026 al 2026
Azioni in circolazione alla fine di ogni anno
Anno Azioni in circolazione Cambia
Non abbastanza dati per le date fornite.
Azioni in circolazione per aziende simili o concorrenti
Azienda Azioni in circolazione Differenza Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 478.91M -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 396.00M -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH